Arkolith/Insider Trading/GTHX/Form 4

Umstead John W. V

Chief Financial OfficerG1 Therapeutics, Inc. (GTHX) · full profile →Form 4 · filed May 15, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$39K
Net Open-Market Flow
-$39K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 13, 2024Sell(S)8K$4.79$39K153K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001562180-24-004063) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML